Our Publications:

Our preprints:

  • Capece M, Tessari A, Mills J, Rampioni Vinciguerra GL, Liu C, McElwain BK, Miles WO, Coppola V, Croce CM, Palmieri D* . A novel auxin-inducible degron system for rapid, cell cycle-specific targeted proteolysis. doi:*corresponding author
  • San A, Palmieri D, Saxena A, Singh S. In silico study predicts a key role of RNA-binding domains 3 and 4 in nucleolin-miRNA interactions. doi: (Accepted on: “PROTEINS: Structure, Function, and Bioinformatics”)

Our selected publications:

  • Palmieri D*, Javorina A, Siddiqui J, Gardner A, Fires A, Chapleau RR, Starr C, Fishel R and Miles WO. Mass COVID-19 patient screening using UvsX and UvsY mediated DNA recombination and high throughput parallel sequencing. Sci Rep. 2022 Mar 8;12(1):4082. doi: 10.1038/s41598-022-08034-1. PMID: 35260723. *corresponding author. 


  • Sheetz T, Mills J, Tessari A, Pawlikowski M, Braddom AE, Posid T, Zynger DL, James C, Embrione V, Parbhoo K, Foray C, Coppola V, Croce CM, Palmieri D*. NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs. Cancers (Basel). 2020 Jul 10;12(7):1861. doi: 10.3390/cancers12071861. Pubmed PMID: 32664322. *corresponding author.


  • Tessari A, Soliman SHA, Orlacchio A, Capece M, Amann JM, Visone R, Carbone DP, Palmieri D, Coppola V. RANBP9 as potential therapeutic target in non-small cell lung cancer. J Cancer Metastasis Treat2020;6doi: 10.20517/2394-4722.2020.32. Epub 2020 Jun 24. PubMed PMID: 34778565; PubMed Central PMCID: PMC8589326.


  • Soliman SHA, Stark AE, Gardner ML, Harshman SW, Breece CC, Amari F, Orlacchio A, Chen M, Tessari A, Martin JA, Visone R, Freitas MA, La Perle KMD, Palmieri D, Coppola V. Tagging enhances histochemical and biochemical detection of Ran Binding Protein 9 in vivo and reveals its interaction with Nucleolin. Sci Rep. 2020 Apr 28;10(1):7138. doi: 10.1038/s41598-020-64047-8. PubMed PMID: 32346083.


  • Mills J, Capece M, Cocucci E, Tessari A, Palmieri D*. Cancer-Derived Extracellular Vesicle-Associated MicroRNAs in Intercellular Communication: One Cell’s Trash Is Another Cell’s Treasure. Int J Mol Sci. 2019 Dec 4;20(24). doi: 10.3390/ijms20246109. Review. PubMed PMID: 31817101. *corresponding author


  • Lo Russo G, Tessari A, Capece M, Galli G, de Braud F, Garassino MC, Palmieri D*. MicroRNAs for the diagnosis and management of Malignant Pleural Mesothelioma: a literature review. in Oncol, 2018 Dec 21. PMID: 30622932. *corresponding author


  • Iorio MV, Palmieri D*. Editorial: From “Junk DNA” to Clinically Relevant Tools for Cancer Diagnosis, Staging, and Tailored Therapies: The Incredible Case of Non-Coding RNAs. Front Oncol. 2019;9:389. doi: 10.3389/fonc.2019.00389. eCollection 2019. PubMed PMID: 31139571. *corresponding author


  • Tessari A, Parbhoo K, Pawlikowski M, Fassan M, Rulli E, Foray C, Fabbri A, Embrione V, Ganzinelli M, Capece M, Campbell MJ, Broggini M, La Perle K, Farina G, Cole S, Marabese M, Hernandez M, Amann JM, Pruneri G, Carbone DP, Garassino MC, Croce CM, Palmieri D, Coppola V. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene. 2018 Aug 3. doi: 10.1038/s41388-018-0424-8. PMID: 30076413


  • Palmieri D, Tessari A, Coppola V. Scorpins in the DNA Damage Response. Int J Mol Sci. 2018 Jun 17;19(6). pii: E1794. doi: 10.3390/ijms19061794. Review. PMID: 29914204


  • D’Avino C, Palmieri D, Braddom A, Zanesi N, James C, Cole S, Salvatore F, Croce CM, De Lorenzo C. A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy. Oncotarget. 2016 Dec 27;7(52):87016-87030. doi10.18632/oncotarget.13522. PMID: 27894092


  • Palmieri D, Scarpa M, Tessari A, Uka R, Amari F, Lee C, Richmond T, Sheetz T, Parvin J, Ludwig T, Croce CM and Coppola Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells. Oncotarget. 2016 Mar 1. doi: 10.18632/oncotarget.7813. PMID: 26943034


  • Cataldo A, Cheung DG, Balsari A, Tagliabue E, Coppola V, Iorio MV, Palmieri D* and Croce miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA Damage Response. Oncotarget. 2016 Jan 5;7(1):786-97. doi: 10.18632/oncotarget.6381. PubMed PMID: 26623722. *corresponding Author


  • Tili E, Chiabai M, Palmieri D*, Brown M, Cui R, Fernandes C, Richmond T, Kim T,  Lagana  A, Veneziano D, Volinia S, Rassenti L, Kipps T, Awadb H, Michaille JJ, and Croce Cooperative activities of Quaking and miR-155 in inflammation and leukemogenesis. Oncotarget. 2015 Sep 22;6(28):24599-610. doi: 10.18632/oncotarget.5248. PMID: 26337206. *Co-first Author


  • Palmieri D, Richmond T, Piovan C, Sheetz T, Zanesi N, Troise F, James C, Wernicke D, Nyei F, Gordon TJ, Salvatore F, Coppola V, Pichiorri F, De Lorenzo C and Croce  A  Human anti- Nucleolin Recombinant Immunoagent for Cancer Therapy. Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9418-23. doi:10.1073/pnas.1507087112. Epub 2015 Jul 13. PMID: 26170308


  • Valentino T, Palmieri D*, Vitiello M, Pierantoni GM, Fusco A, Fedele PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context. Cell Death Dis. 2013 Dec 12;4:e963. doi: 10.1038/cddis.2013.500. PMID: 24336083 *Co-first Author


  • Pichiorri F, Palmieri D*, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med. 2013 May 6;210(5):951-68. doi: 10.1084/jem.20120950. PMID: 28104811. *Co-first Author


  • Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 2012 Aug;6(4):458-72. doi: 10.1016/j.molonc.2012.03.003. PMID: 22578566


  • D’Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G,  Fedele  M,  Croce  CM, Trouillas J, Fusco Altered microRNA expression profile in human pituitary GH adenomas: down- regulation of miRNA targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab. 2012 Jul;97(7):E1128-38. doi: 10.1210/jc.2011-3482. PMID: 22564666


  • Palmieri D, D’Angelo D, Valentino T, De Martino I, Ferraro A, Wierinckx A, Fedele M, Trouillas J and Fusco Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene. 2012 Aug 23;31(34):3857-65. doi: 10.1038/onc.2011.557. PMID: 22139073


  • Palmieri D, Valentino T, De Martino I, Esposito F, Cappabianca P, Wierinckx A, Vitiello M, Lombardi G, Colao A, Trouillas J, Pierantoni GM, Fusco A and Fedele Pit-1 upregulation by HMGA proteins has a role in pituitary tumorigenesis. Endocr Relat Cancer. 2012 Apr 10;19(2):123-35. doi: 10.1530/ERC-11-0135. PMID: 22199144


  • Palmieri D, Valentino T, D’Angelo D, De Martino I, Postiglione I, Pacelli R, Croce CM, Fedele M, Fusco HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene. 2011 Jul 7;30(27):3024-35. doi: 10.1038/onc.2011.21. Epub 2011 Feb 21. PMID: 21339738


  • Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM, Helin K, Croce CM, Fusco HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell. 2006 Jun;9(6):459-71. PMID: 16766265


The full list of our publications is available here.